CN104922123A - Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia - Google Patents
Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia Download PDFInfo
- Publication number
- CN104922123A CN104922123A CN201510280208.8A CN201510280208A CN104922123A CN 104922123 A CN104922123 A CN 104922123A CN 201510280208 A CN201510280208 A CN 201510280208A CN 104922123 A CN104922123 A CN 104922123A
- Authority
- CN
- China
- Prior art keywords
- daphmalenine
- anemia
- application
- preparation
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BNSQPPYRCUIFLZ-LSLDVNGTSA-N daphmalenine A Natural products C1C[C@@]2(O)C(=O)C[C@@H]3[C@]22OC[C@]4(CCC(=O)CC)[C@H]1CN(C)C[C@@]42C[C@H]3C(=O)OC BNSQPPYRCUIFLZ-LSLDVNGTSA-N 0.000 title claims abstract description 44
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 208000032467 Aplastic anaemia Diseases 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title abstract description 8
- 229940079593 drug Drugs 0.000 title abstract description 5
- 206010021074 Hypoplastic anaemia Diseases 0.000 title abstract 5
- 208000007502 anemia Diseases 0.000 claims description 43
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 23
- 241001597008 Nomeidae Species 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- -1 phosphate amine Chemical class 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000002607 hemopoietic effect Effects 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- 208000035126 Facies Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000010437 erythropoiesis Effects 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 3
- 208000035220 Dyserythropoietic Congenital Anemia Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000004440 congenital dyserythropoietic anemia Diseases 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000208664 Daphniphyllum Species 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229930186810 daphmalenine Natural products 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 231100001016 megaloblastic anemia Toxicity 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 206010015287 Erythropenia Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of a drug for resisting red blood cell hypoplastic anemia. The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a Daphmalenine A derivative, a preparation method, and an application of the derivative to preparation of the drug for resisting the red blood cell hypoplastic anemia. The new Daphmalenine A derivative is synthesized, and the preparation method of the derivative is disclosed. Pharmacology experiments show that the Daphmalenine A derivative has an effect of resisting red blood cell hypoplastic anemia and is valuable in developing of the drug for resisting the red blood cell hypoplastic anemia.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to Daphmalenine A derivant, preparation method and its usage.
Background technology
Based on different clinical characters, anemia has different classification.As: divide acute and chronic anemia by anemia tempo; Hyperplastic anemia (as hemolytic anemia, iron deficiency anemia, megaloblastic anemia etc.) and Hypolasia anemia (as aplastic anemia) is divided by bone marrow red system proliferative conditions.
The normal classification from anemia pathogenesis and the cause of disease clinically:
1. erythropoiesis minimizing property anemia
The anomalous effects erythropoiesis of hematopoietic cell, marrow stromal cell and hemopoietic raw material, can form erythropoiesis minimizing property anemia.
(1) hematopoietic stem/progenitor cells caused by abnormal anemia
1) aplastic anemia (AA) AA is a kind of marrow hematopoiesis function failure disease, damages relevant with the hematopoietic stem/progenitor cells of former and secondary.The pathogenesis of parts whole blood cytopenia and B cell produce anti-medullary cell autoantibody, and then destroy or suppress myeloid element relevant.
2) pure red cell aplasia anemia (PRCA) PRCA refers to that bone marrow erythroid hematopoiesis stem/progenitor cells suffers damage, and then causes anemia.According to the cause of disease, this disease can be divided into congenital and posteriority two class.Congenital PRCA and Diamond-Blackfan syndrome is caused by heredity; Posteriority PRCA comprises former, secondary two class.Scholar is had to find have self EPO or normoblast antibody in part constitutional PRCA patients serum.Secondary cases PRCA mainly contains medicine relationship type, (antibacterial and virus, as piconavirus B to infect relationship type
19, hepatitis virus etc.), autoimmune disease relationship type, lymphoproliferative disease relationship type (as thymoma, lymphoma, plasma cell dyscrasia and Lymphocytic leukemia etc.) and acute aplastic crisis etc.
3) congenital dyserythropoietic anemia (CDA) CDA be a class heritability red system stem/progenitor cells optimum clone caused by abnormal, the refractory anemia that is feature with red system ineffective hematopoiesis and paramophia.According to mode of inheritance, this disease can be divided into the hidden flight of steps leading to a palace hall genotype of autosome and dominant inheritance's type.
4) these disease hematopoietic stem/progenitor cells of hemopoietic system malignant clone disease there occurs the exception of matter, comprise myelodysplastic syndrome and all kinds of hematopoietic system cancer disease as leukemia etc.The former is because DH, high hypertrophy, and hemolysis in situ, appears in high apoptosis; The latter's neoplastic hyperplasia, low apoptosis and low differentiation, hemopoietic regulates and is also affected, thus makes normal mature erythrocytopenia and anemia occurs.
(2) hematopoieticmicroenviron-ment caused by abnormal anemia
Hematopoieticmicroenviron-ment comprises bone marrow matrix, stromal cell and cytokine.
1) bone marrow neoplasms of sick, the various extramedullary tumor disease of bone marrow matrix and stromal cell impaired Anemia BMN, myelofibrosis, myelosclerosis, marble and various infection or non-infectious osteomyelitis, all can because of damage bone marrow matrix and stromal cell, hematopoieticmicroenviron-ment occurs abnormal and affects hemopoietic.
2) hematopoietic regulators horizontal abnormality Anemia stem cell factor (SCF), interleukin (IL), grain-monosystem colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), erythropoietin (EPO), thrombopoietin (TPO), PDGF (TGF), tumor necrosis factor (TNF) and interferon (IFN) etc. all have positive negative regulation hemoposieis.Renal insufficiency, hepatopathy and hypophysis or hypothyroidism etc. time to produce EPO not enough; Neoplastic disease or some viral infection can induce body to produce more hemopoietic negative regulatory factor as TNF, IFN, inflammatory factor etc., all can cause ACD (ACD).
(3) hemopoietic insufficient raw material or Use barriers Anemia
Hemopoietic raw material refers to hematopoietic cell proliferation, differentiation, the necessary material of metabolism, as protein, lipid, vitamin (folic acid, vitamin B12 etc.), trace element (ferrum, copper, zinc etc.) etc.Any one hemopoietic insufficient raw material or Use barriers all may cause erythropoiesis to reduce.
1) folic acid or vitamin B
12to lack or Use barriers Anemia causes the megaloblastic anemia that body folic acid or vitamin B12 definitely or relatively lack or Use barriers can cause due to various physiology or pathological factor.
2) iron deficiency and ferrum Use barriers anemia this be modal anemia clinically.Iron deficiency and ferrum Use barriers affect haemachrome synthesis, have and claim such anemia to be haemachrome resulting anomaly anemia.The red cell morphology of such anemia diminishes, and central olistherozone expands, and belongs to microcytic hypochromic anemia.
2. hemolytic anemia (HA)
I.e. hematoclasis too much property anemia.
3. hemorrhagic anemia
Divide acute and chronic according to the speed of losing blood, chronic blood loss anemia often merges iron deficiency anemia.Can be divided into disorders of blood coagulation (as idiopathic thrombocytopenic purpura, hemophilia and severe liver disease etc.) make peace non-go out caused two classes of disorders of blood coagulation (as wound, tumor, tuberculosis, bronchiectasis, peptic ulcer, hemorrhoid and gynaecopathia etc.).
From natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus the potential drug obtaining high-efficiency low-toxicity there is important value most.
The Compound D aphmalenine A that the present invention relates to is one and within 2011, delivers (Yu Zhang et al., 2011.Daphmalenines A and B:Two New Alkaloids with Unusual Skeletons from Daphniphyllum himalense.Eur.J.Org.Chem.2011, 4103 – 4107) compound, we have carried out structural modification to Compound D aphmalenine A, obtain a new Daphmalenine A derivant, and its anti-erythrocyte low property anemia activity is evaluated, it is active that it has anti-erythrocyte low property anemia.
Summary of the invention
The invention discloses a Daphmalenine A derivant, its structure is:
Daphmalenine A derivant (III) of the present invention is by method preparation below:
(1) Daphmalenine A (I) and glycol dibromide are obtained by reacting the O-bromoethyl derivant (II) of Daphmalenine A;
(2) O-bromoethyl derivant (II) and the diethylamine generation substitution reaction of Daphmalenine A obtain O-(diethylin) ethyl derivative (III) of Daphmalenine A.
The preparation method of O-(diethylin) ethyl derivative (III) of further Daphmalenine A is: 419mg Compound D aphmalenine A (I) is dissolved in 10mL benzene by (1), the tetrabutyl ammonium bromide of 0.08g is added in solution, the glycol dibromide of 7.520g and 50% sodium hydroxide solution of 6mL; Mixture stirs 12h at 35 degrees Celsius; After 12h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution; Then use water and saturated common salt water washing 4 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product; Product crude product purification by silica gel column chromatography, mobile phase is: petroleum ether/acetone=100:1.5, v/v, collects the yellow yellow solid concentrating elution band namely to obtain the O-bromoethyl derivant (II) of Daphmalenine A.
(2) by Compound II per (263mg, 0.5mmol) be dissolved in the middle of 20mL acetonitrile, add Anhydrous potassium carbonate (345mg wherein, 2.5mmol), potassium iodide (84mg, 0.5mmol) with diethylamine (1460mg, 20mmol), mixture reflux 10h.After reaction terminates, reactant liquor is poured in frozen water, with equivalent dichloromethane extraction four times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.(mobile phase is product crude product purification by silica gel column chromatography: petroleum ether/acetone=100:1, v/v), collect the yellow yellow gummy solid (196.8mg, 76%) concentrating elution band namely to obtain O-(diethylin) ethyl derivative (III) of Daphmalenine A.
Compound disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
The object of the present invention is to provide the new application of the compounds of this invention III in pharmaceutical field.
The compounds of this invention III is as the application in preparation treatment erythrocyte low property anemia medicine.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation of embodiment 1 Compound D aphmalenine A
Document (the Yu Zhang et al. that the people such as the preparation method reference Yu Zhang of Compound D aphmalenine A (I) deliver, 2011.Daphmalenines A and B:Two New Alkaloids with Unusual Skeletons from Daphniphyllum himalense.Eur.J.Org.Chem.2011,4103 – 4107) method.
The synthesis of the O-bromoethyl derivant (II) of embodiment 2 Daphmalenine A
By Compound I (419mg, 1.00mmol) be dissolved in 10mL benzene, add in solution tetrabutyl ammonium bromide (TBAB) (0.08g), 1,50% sodium hydroxide solution of 2-Bromofume (7.520g, 40.00mmol) and 6mL.Mixture stirs 12h at 35 degrees Celsius.After 12h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution.Then use water and saturated common salt water washing 4 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:1.5, v/v), collects the yellow yellow solid (320mg, 61%) concentrating elution band namely to obtain Compound II per.
1H NMR(500MHz,DMSO-d
6)δ3.84(d,J＝1.6Hz,2H),3.76–3.50(m,5H),3.42(s,2H),3.09(s,1H),2.99(s,1H),2.88(s,1H),2.70(s,1H),2.64(d,J＝19.1Hz,3H),2.45(d,J＝5.6Hz,3H),2.33(s,1H),2.19–2.12(m,5H),2.07(s,1H),1.97(d,J＝9.2Hz,3H),1.84–1.76(m,3H),1.69(s,1H),1.15(s,1H),1.04(s,3H)。
13C NMR(125MHz,DMSO-d6)δ219.71(s),211.07(s),176.65(s),66.24(s),65.38(s),63.59(s),59.42(s),54.79(s),52.18(s),46.22(s),46.01(s),45.50(s),45.27(s),40.33(s),37.86(s),37.61(s),36.27(s),34.26(s),30.89(s),28.52(s),26.04(s),25.24(s),8.50(s)。
HRMS(ESI)m/z[M+H]
+calcd for C
25H
37BrNO
6:526.1804；found 526.1801.
The synthesis of O-(diethylin) ethyl derivative (III) of embodiment 3 Daphmalenine A
Compound II per (263mg, 0.5mmol) is dissolved in the middle of 20mL acetonitrile, adds Anhydrous potassium carbonate (345mg wherein, 2.5mmol), potassium iodide (84mg, 0.5mmol) and diethylamine (1460mg, 20mmol), mixture reflux 10h.After reaction terminates, reactant liquor is poured in frozen water, with equivalent dichloromethane extraction four times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.(mobile phase is product crude product purification by silica gel column chromatography: petroleum ether/acetone=100:1, v/v), collect the yellow yellow gummy solid (196.8mg, 76%) concentrating elution band namely to obtain O-(diethylin) ethyl derivative (III) of Daphmalenine A.
1H NMR(500MHz,DMSO-d6)δ3.78(s,1H),3.68(s,3H),3.45(s,2H),3.09(s,1H),2.94(d,J＝59.8Hz,5H),2.79(s,1H),2.71(d,J＝10.0Hz,2H),2.63(d,J＝1.4Hz,4H),2.43(t,J＝16.7Hz,3H),2.36(d,J＝5.9Hz,1H),2.19–2.12(m,5H),2.09– 2.00(m,4H),1.90(dd,J＝10.7,8.0Hz,1H),1.85(d,J＝23.9Hz,1H),1.72(s,1H),1.65(s,1H),1.13(d,J＝7.0Hz,7H),1.06(s,3H).
13C NMR(125MHz,,DMSO-d6)δ219.80(s),211.16(s),176.74(s),66.30(s),63.64(s),61.62(s),59.51(s),54.88(s),52.27(s),51.99(s),47.76(s),46.30(s),46.06(s),45.55(s),45.26(s),40.31(s),37.86(s),37.63(s),36.28(s),30.87(s),28.53(s),26.01(s),25.23(s),12.37(s),8.50(s).
HRMS(ESI):m/z[M+H]
+calcd for C
29H
47N
2O
6:519.3434；found:519.3429。
Embodiment 4 compound III anti-erythrocyte low property anemia is tested
Test the therapeutical effect of 1 compound III to post hemorrhagic mice
ICR mice 24, ♀ ♂ half and half, is divided into 4 groups.Except normal saline group, other group every mice is from orbital vein blood-letting 0.5ml, get blood survey after 24h again and all respectively organize index, then continuously gastric infusion 1 week and blood-letting every day 0.5ml after administration, after last administration 1h, get the full whole bliid platelet analyzer of blood F-800 from orbital venous plexus and carry out red blood cell count(RBC) (10
12/ L).
Triethylamine (compound IV) is commercially available analytical pure.
Table 1 compound III is to because of caused oligocythemic therapeutical effect of losing blood
Compare with model group: * p<0.05
Result shows, blood-letting mice, after taking compound III and treating 7 days, is compared with model group, and its erythrocyte is significantly higher than model group, close to normal saline group.And compound IV acts on without this.
Two, compound III causes oligocythemic therapeutical effect to cyclophosphamide
To the preventive and therapeutic effect ICR mice 40 of mouse bone marrow cells hemopoietic function damage, ♀ ♂ dual-purpose, is divided into 4 groups (n=10), i.e. normal saline group, modeling group, compound III 1.2mg/kg group, compound IV 1.2mg/kg group, oral administration, every day 1 time.0th, except normal saline group, other respectively organized mice lumbar injection cycli phosphate amine 80mg/kg respectively, then continued administration 3 days on 5th, 10.1h after last administration, gets blood from orbital venous plexus, surveys RBC number (10
12/ L).
Table 2 compound III is on the erythrocytic impact of caused by cyclophosphamide
Compare with model group: * * p<0.01
Result shows, compares with normal saline group, and cycli phosphate amine can make mouse bone marrow cells damage, and causes peripheral blood cells to decline, and compound III group compares with model group, obviously can resist cycli phosphate amine induced mice red blood cell decreased.And compound IV acts on without this.
Three, compound III is to oligocythemic therapeutical effect caused by benzene
Impact on Induced Aplastic Anemia Mice: Kunming mouse 40, ♀ ♂ dual-purpose, is divided into 4 groups (n=10), except normal saline group, other group mouse subcutaneous injection benzene 0.5ml/kg, continuous 12 days, the same day of modeling, oral administration simultaneously, every day 1 time, totally 18 days, 1h after last administration, orbital venous plexus gets blood, surveys erythrocyte.
Table 3 compound III is to oligocythemic therapeutical effect caused by benzene
Compare with model group: * * p<0.01
Result shows, administration group compares with model group, obviously can resist the erythrocytic decline of Induced Aplastic Anemia Mice caused by benzene.And compound IV acts on without this.
Conclusion: compound III significantly can raise erythrocyte, can be used for preparing the medicine for the treatment of anemia.And compound IV significantly can not raise erythrocyte, can not be used for preparing the medicine for the treatment of anemia.
The preparation of embodiment 5 compound III tablet involved in the present invention
Get the one in the middle of 20 g of compound III or its pharmaceutically acceptable salt, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
The preparation of embodiment 6 compound III capsule involved in the present invention
Get the one in the middle of 20 g of compound III or its pharmaceutically acceptable salt, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Claims (5)
1. one kind has Daphmalenine A derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof of structure shown in formula III:
2. a kind of Daphmalenine A derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof with structure shown in formula III as claimed in claim 1, is characterized by: described erythrocyte low property anemia is caused by losing blood.
3. a kind of Daphmalenine A derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof with structure shown in formula III as claimed in claim 1, is characterized by: described erythrocyte low property anemia is that the erythrocyte caused by chemical substance is low.
4. a kind of Daphmalenine A derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof with structure shown in formula III as claimed in claim 3, it is characterized by: described chemical substance is benzene, described erythrocyte low property anemia is the aplastic anemia caused by benzene.
5. a kind of Daphmalenine A derivant (III) and the application of pharmaceutically acceptable salt in treatment erythrocyte low property anemia medicine thereof with structure shown in formula III as claimed in claim 3, it is characterized by: described chemical substance is cycli phosphate amine, described erythrocyte low property anemia is red blood cell decreased caused by cycli phosphate amine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510280208.8A CN104922123A (en) | 2015-05-27 | 2015-05-27 | Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510280208.8A CN104922123A (en) | 2015-05-27 | 2015-05-27 | Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104922123A true CN104922123A (en) | 2015-09-23 |
Family
ID=54109782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510280208.8A Pending CN104922123A (en) | 2015-05-27 | 2015-05-27 | Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104922123A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343085A (en) * | 2015-10-14 | 2016-02-24 | 南京大学 | Composition and application thereof in low erythrocyte anemia resistant drugs |
| CN105497038A (en) * | 2015-12-29 | 2016-04-20 | 南京大学 | Composition and application thereof to low-erythrocyte anemia resistant medicament |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127421A (en) * | 2014-07-31 | 2014-11-05 | 南京广康协生物医药技术有限公司 | Application of O-(piperidyl)ethyl derivative of Cleistanone in preparation of anti-low erythrocyte anemia drugs |
| CN104147014A (en) * | 2014-06-27 | 2014-11-19 | 南京广康协生物医药技术有限公司 | Application of Cleistanone diethylamine derivative in preparation of drugs for resisting anemia caused by low red blood cell level |
| CN104288159A (en) * | 2014-11-05 | 2015-01-21 | 南京大学 | Application of O-(piperazinyl) ethyl derivative of cleistanone to preparation of medicine for resisting erythrocyte hypoplastic anemia |
-
2015
- 2015-05-27 CN CN201510280208.8A patent/CN104922123A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104147014A (en) * | 2014-06-27 | 2014-11-19 | 南京广康协生物医药技术有限公司 | Application of Cleistanone diethylamine derivative in preparation of drugs for resisting anemia caused by low red blood cell level |
| CN104127421A (en) * | 2014-07-31 | 2014-11-05 | 南京广康协生物医药技术有限公司 | Application of O-(piperidyl)ethyl derivative of Cleistanone in preparation of anti-low erythrocyte anemia drugs |
| CN104288159A (en) * | 2014-11-05 | 2015-01-21 | 南京大学 | Application of O-(piperazinyl) ethyl derivative of cleistanone to preparation of medicine for resisting erythrocyte hypoplastic anemia |
Non-Patent Citations (1)
| Title |
|---|
| YU ZHANG等: "Daphmalenines A and B: Two New Alkaloids with Unusual Skeletons from Daphniphyllum himalense", 《EUR. J. ORG. CHEM.》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343085A (en) * | 2015-10-14 | 2016-02-24 | 南京大学 | Composition and application thereof in low erythrocyte anemia resistant drugs |
| CN105497038A (en) * | 2015-12-29 | 2016-04-20 | 南京大学 | Composition and application thereof to low-erythrocyte anemia resistant medicament |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104127421B (en) | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone | |
| CN104288159B (en) | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperazinyl) ethyl derivative of Cleistanone | |
| CN104147014B (en) | The application in preparing anti-erythrocyte low property anemia medicine of the diethylamine derivative of Cleistanone Cleistanone | |
| CN104922123A (en) | Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia | |
| CN102627685B (en) | Nitric oxide-donating glutathione compound, preparation method and medical purpose thereof | |
| CN104800222A (en) | Application of O-(benzimidazolyl) ethyl derivative of cleistanone in preparing drug for preventing red blood cell hypoplastic anemia | |
| CN105250308A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105078985A (en) | Composition 53083001030571 and application of composition 53083001030571 to drug for resisting low-hematocrit anemia | |
| CN104887667A (en) | Application of Daphmalenine A ramification to preparing medicine for resisting low red blood cell anemia | |
| CN105287570A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105250258A (en) | Composition and application of composition in medicine for resistance of erythrocyte low anemia | |
| CN105250293A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105193815A (en) | Composition and application thereof in drugs for preventing low-erythrocyte anemia | |
| CN105287525A (en) | Composition and application of composition in medicine for resisting low red blood cell type anemia | |
| CN106038551A (en) | Application of composition of Schiglautone A derivatives in preparation of low-erythrocyte anemia preventive drugs | |
| CN104758295A (en) | Application of O-(triazolyl)ethyl derivative of cleistanone in preparation of anti-low-erythrocyte anemia drug | |
| CN105343085A (en) | Composition and application thereof in low erythrocyte anemia resistant drugs | |
| CN105497038A (en) | Composition and application thereof to low-erythrocyte anemia resistant medicament | |
| CN105287455A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105343083A (en) | Composition and application of composition in medicines for resisting low erythrocyte anemia | |
| CN105395555A (en) | Composition and application thereof to medicine resistant to red cell hypoplastic anemia | |
| CN105616403A (en) | Composition and application thereof to low red blood cell anemia resisting medicine | |
| CN106074479A (en) | The compositions of the derivant of Artalbic acid is used for preparing anti-erythrocyte low property anemia medicine | |
| CN107929288A (en) | The miscellaneous source terpene piperazinyl of guava dialdehyde and tetrazole radical derivative composition are used to prepare anti-anemia action medicine | |
| CN108078985A (en) | The preparation method and its application in anti-anemia action drug of the miscellaneous source terpene imidazole radicals of guava dialdehyde and two hydroxyethylamine derivative compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150923 |
|
| RJ01 | Rejection of invention patent application after publication |